SMB00962
Phenylacetyl-L-glutamine
≥95%, research grade
别名:
(S)-5-Amino-5-oxo-2-(2-phenylacetamido)pentanoic acid, N-Phenylacetylglutamine, Phenylacetylglutamine
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C13H16N2O4
化学文摘社编号:
分子量:
264.28
UNSPSC Code:
12352209
NACRES:
NA.26
MDL number:
biological source
synthetic
Quality Level
assay
≥95%
form
powder
storage condition
(Store in tight containers in a cool and dry place)
technique(s)
HPLC: suitable
color
off-white
cation traces
C: 56.1—62%
storage temp.
room temp
SMILES string
N([C@@H](CCC(=O)N)C(=O)O)C(=O)Cc1ccccc1
InChI
1S/C13H16N2O4/c14-11(16)7-6-10(13(18)19)15-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H2,14,16)(H,15,17)(H,18,19)/t10-/m0/s1
InChI key
JFLIEFSWGNOPJJ-JTQLQIEISA-N
General description
Phenylacetyl-L-glutamine is a primary human metabolite formed from phenylacetate in presence of glutamine in the liver. It is also considered as a gut-microbiome derived uremic toxin. Phenylacetyl-L-glutamine urine levels serve as an effective biomarker for the excretion of nitrogenous waste. Also, peripheral artery disease patients exhibit higher circulating concentration of phenylacetyl-L-glutamine, and high plasma phenylacetyl-L-glutamine levels are associated with cardiovascular disease.
Application
Phenylacetyl-ʟ-glutamine is a versatile compound that finds application in microbiome and metabolomics research.
Features and Benefits
- Ideal for biochemical, microbiome and metabolomics studies
- High quality product for research applications
Other Notes
For additional information on our range of Biochemicals, please complete this form.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Lu Dai et al.
Toxins, 12(6) (2020-05-31)
Gut microbial metabolism is not only an important source of uremic toxins but may also help to maintain the vitamin K stores of the host. We hypothesized that sevelamer therapy, a commonly used phosphate binder in patients with end-stage kidney
Sandi M Azab et al.
Journal of clinical medicine, 9(6) (2020-06-21)
Peripheral artery disease (PAD) is characterized by the atherosclerotic narrowing of lower limb vessels, leading to ischemic muscle pain in older persons. Some patients experience progression to advanced chronic limb-threatening ischemia (CLTI) with poor long-term survivorship. Herein, we performed serum
Ina Nemet et al.
Cell, 180(5), 862-877 (2020-03-07)
Using untargeted metabolomics (n = 1,162 subjects), the plasma metabolite (m/z = 265.1188) phenylacetylglutamine (PAGln) was discovered and then shown in an independent cohort (n = 4,000 subjects) to be associated with cardiovascular disease (CVD) and incident major adverse cardiovascular events (myocardial infarction
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SMB00962-250MG | 04065265631792 |
| SMB00962-25MG | 04065265631808 |